Nevertheless, the CTX140 1q6d (or perhaps a similar regimen given weekly) may be a promising option to consider for controlling tumor growth even as a monotherapy and the human equivalent of the protocol may be an attractive therapy for maintenance or palliative care therapy for breast cancer, despite the potential of being unsuitable for combination with immunotherapies targeting PD-L1. The gene discussed is CD274; the disease is neoplasm.